Abstract
Parafibromin is a putative tumor suppressor encoded by HRPT2, mutations in which have been implicated in the familial tumor syndrome hyperparathyroidism jaw tumor syndrome (HPT-JT), and sporadic parathyroid carcinoma. Recently, parafibromin has been shown to be an accessory factor for RNA polymerase II as part of the human Paf1 complex, suggesting, as has been shown for its yeast homologue (Cdc73), that it may have a role as an important regulator of transcription. Parafibromin has also been shown to interact with a histone methyltransferase complex that methylates histone H3 and to inhibit proliferation when overexpressed in mammalian cell lines. Despite these findings, the cellular localization of parafibromin has been controversial, with reports of both nuclear and nucleocytoplasmic localization. We have expressed wild-type and mutant parafibromin tagged with enhanced green fluorescent protein and have identified a functional bipartite nuclear localization signal (NLS) at residues 125–139 (nucleotides 373–417), KRAADEVLAEAKKPR, that is evolutionarily conserved and critical for the nuclear localization of parafibromin. We have also shown that the C-terminal arm of this bipartite NLS plays the primary role in nuclear localization. In support of these findings, specific HRPT2 mutations identified in HPT-JT or sporadic parathyroid carcinoma predicted to truncate parafibromin upstream of or within this NLS disrupt nuclear localization.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Betz JL, Chang M, Washburn TM, Porter SE, Mueller CL and Jaehning JA . (2002). Mol. Genet. Genom., 268, 272–285.
Carpten JD, Robbins CM, Villablanca A, Forsberg L, Presciuttini S, Bailey-Wilson J, Simonds WF, Gillanders EM, Kennedy AM, Chen JD, Agarwal SK, Sood R, Jones MP, Moses TY, Haven C, Petillo D, Leotlela PD, Harding B, Cameron D, Pannett AA, Hoog A, Heath H, James-Newton LA, Robinson B, Zarbo RJ, Cavaco BM, Wassif W, Perrier ND, Rosen IB, Kristoffersson U, Turnpenny PD, Farnebo L-O, Besser GM, Jackson CE, Morreau H, Trent JM, Thakker RV, Marx SJ, The BT, Larsson C and Hobbs MR . (2002). Nat. Genet., 32, 676–680.
Chen JD, Morrison C, Zhang C, Kahnoski K, Carpten JD and Teh BT . (2003). J. Intern. Med., 253, 634–642.
Dingwall C and Laskey R . (1991). Trends Biochem. Sci., 16, 478–481.
Hampsey M and Reinberg D . (2003). Cell, 113, 429–432.
Henderson BR and Eleftheriou A . (2000). Exp. Cell Res., 256, 213–224.
Howell VM, Haven CJ, Kahnoski K, Khoo SK, Petillo D, Chen J, Fleuren GJ, Robinson BG, Delbridge LW, Philips J, Nelson AE, Krause U, Hammje K, Dralle H, Hoang-Vu C, Gimm O, Marsh DJ, Morreau H and Teh BT . (2003). J. Med. Genet., 40, 657–663.
Hsi ED, Zukerberg LR, Yang WI and Arnold A . (1996). J. Clin. Endocrinol. Metab., 81, 1736–1739.
Huang TT and Miyamoto S . (2001). Mol. Cell. Biol., 21, 4737–4747.
Jans DA, Briggs LJ, Gustin SE, Jans P, Ford S and Young IG . (1997). FEBS Lett., 406, 315–320.
Linder B, Newman R, Jones LK, Debernardi S, Young BD, Freemont P, Verrijzer CP and Saha V . (2000). J. Mol. Biol., 299, 369–378.
Porter SE, Penheiter KL and Jaehning JA . (2005). Eukaryotic Cell, 4, 209–220.
Robbins J, Dilworth SM, Laskey RA and Dingwall C . (1991). Cell, 64, 615–623.
Rozenblatt-Rozen O, Hughes CM, Nannepaga SJ, Shanmugam KS, Copeland TD, Guszczynski T, Resau JH and Meyerson M . (2005). Mol. Cell. Biol., 25, 612–620.
Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA and Baxter RC . (2000). J. Biol. Chem., 275, 23462–23470.
Shattuck TM, Valimaki S, Obara T, Gaz RD, Clark OH, Shoback D, Wierman ME, Tojo K, Robbins CM, Carpten JD, Farnebo L-O, Larsson C and Arnold A . (2003). N. Engl. J. Med., 349, 1722–1729.
Simonds WF, Robbins CM, Agarwal SK, Hendy GN, Carpten JD and Marx SJ . (2004). J. Clin. Endocrinol. Metab., 89, 96–102.
Stommel JM, Marchenko ND, Jimenez GS, Moll UM, Hope TJ and Wahl GM . (1999). EMBO J., 18, 1660–1672.
Tan M-H, Morrison C, Wang P, Yang X, Haven CJ, Zhang C, Zhao P, Tretiakova MS, Korpi-Hyovalti E, Burgess JR, Soo KC, Cheah W-K, Cao B, Resau J, Morreau H and Teh BT . (2004). Clin. Cancer Res., 10, 6629–6637.
van Koningsbruggen S, Dirks RW, Mommaas AM, Onderwater JJ, Deidda G, Padberg GW, Frants RR and van der Maarel SM . (2004). J. Med. Genet., 41, e46.
Villablanca A, Calender A, Forsberg L, Hoog A, Cheng J-D, Petillo D, Bauters C, Kahnoski K, Ebeling T, Salmela P, Richardson A-L, Delbridge L, Meyrier A, Proye C, Carpten JD, Teh BT, Robinson BG and Larsson C . (2004). J. Med. Genet., 41, e32.
Woodard GE, Lin L, Zhang J-H, Agarwal SK, Marx SJ and Simonds WF . (2004). Oncogene, 24, 1272–1276.
Zhang L, Brereton HM, Hahn M, Froscio M, Tilley WD, Brown MP and Barritt GJ . (2003). Cancer Gene Ther., 10, 611–625.
Acknowledgements
Dr L Zhang, Flinders University, Adelaide, South Australia is thanked for his kind gift of EGFP vectors pEGF-C1 and pEGF-N1. This work was supported by the Australian National Health and Medical Research Council [302161]. DJM is the recipient of a Cancer Institute NSW Fellowship.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hahn, M., Marsh, D. Identification of a functional bipartite nuclear localization signal in the tumor suppressor parafibromin. Oncogene 24, 6241–6248 (2005). https://doi.org/10.1038/sj.onc.1208778
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1208778
Keywords
This article is cited by
-
Not All Parafibromin Deficiency Relates to Parathyroid Carcinoma: The Role of Morphological Assessment
Endocrine Pathology (2024)
-
A two-generation hyperparathyroidism-jaw tumor (HPT-JT) syndrome family: clinical presentations, pathological characteristics and genetic analysis: a case report
Diagnostic Pathology (2022)
-
Overview of the 2022 WHO Classification of Parathyroid Tumors
Endocrine Pathology (2022)
-
Genomics and Epigenomics in Parathyroid Neoplasia: from Bench to Surgical Pathology Practice
Endocrine Pathology (2021)
-
Crystal structure of the N-terminal domain of human CDC73 and its implications for the hyperparathyroidism-jaw tumor (HPT-JT) syndrome
Scientific Reports (2017)